Methods and compositions including methscopolamine nitrate
OwnerDavid Prestoninventor
Life of this patent
Estimating the term…
Abstract
Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine nitrate is the preferred anticholinergic agent. The sedative agent may be a benzodiazepine or a barbiturate. Particularly, the sedative agent may be chlordiazepoxide hydrochloride, diazepam, or phenobarbital. Various methods using the compositions to alleviate gastrointestinal disorders or symptoms thereof are also provided.
Claims43
A therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of a blended mixture of an anticholinergic agent comprising methscopolamine nitrate and a sedative agent comprising chlordiazepoxide hydrochloride.
A therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of a blended mixture of an anticholinergic agent comprising methscopolamine nitrate and a sedative agent comprising diazepam.
A therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of a blended mixture of an anticholinergic agent comprising methscopolamine nitrate and a sedative agent comprising phenobarbital.
A therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of a blended mixture of methscopolamine nitrate and chlordiazepoxide hydrochloride wherein the ratio of the methscopolamine nitrate to the chlordiazepoxide is about 0.5:1 to about 1:1.
A therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of methscopolamine nitrate for oral administration in an amount of about 2.0 to about 5.0 mg per dose.
A method of alleviating at least one gastrointestinal disorder or at least one symptom of a gastrointestinal disorder in a human patient, the method comprising administering to the patient a therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of a blended mixture of methscopolamine nitrate and chlordiazepoxide hydrochloride.
A method of alleviating at least one gastrointestinal disorder or at least one symptom of a gastrointestinal disorder in a human patient, the method comprising administering to the patient a therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of a blended mixture of methscopolamine nitrate and diazepam.
A method of alleviating at least one gastrointestinal disorder or at least one symptom of a gastrointestinal disorder in a human patient, the method comprising administering to the patient a therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of a blended mixture of methscopolamine nitrate and phenobarbital.
A method of alleviating at least one gastrointestinal disorder or at least one symptom of a gastrointestinal disorder in a human patient, the method comprising administering to the patient a therapeutic pharmaceutical composition consisting essentially of a therapeutically effective amount of methscopolamine nitrate.
Dependencies are inferred from the claim text.